Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL-1

Abstract

Dupilumab is well tolerated and improves clinical outcomes in patients with asthma and high eosinophils (≥500 cells·µL−1). Improvements in clinical outcomes correlate with eosinophil counts, demonstrating dupilumab efficacy in those with high eosinophils. https://bit.ly/3Jxvicb

Trial registration: ClinicalTrials.gov NCT02414854.

Conflict of interest statement

Conflict of interest: K.F. Rabe is a consultant for and received speaker fees from AstraZeneca, Boehringer Ingelheim, Novartis, Sanofi and Teva. I.D. Pavord received speaker fees from Aerocrine AB, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Novartis and Teva; received payments for organising education events from AstraZeneca and Teva; received consulting fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Dey Pharma, Genentech, GlaxoSmithKline, Knopp Biosciences, Merck, MSD, Napp Pharmaceuticals, Novartis, Regeneron Pharmaceuticals, Inc., RespiVert, Sanofi, Schering-Plough and Teva; received international scientific meeting sponsorship from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Napp Pharmaceuticals and Teva; and received research grants from Chiesi; and is consultant for Regeneron Pharmaceuticals, Inc. and Sanofi. M. Castro received research support from the American Lung Association, AstraZeneca, GlaxoSmithKline, NIH, Novartis, PCORI, Pulmatrix, Sanofi-Aventis and Shionogi; is a consultant for Genentech, Novartis, Sanofi-Aventis and Teva; received speaker fees from AstraZeneca, Genentech, GlaxoSmithKline, Regeneron Pharmaceuticals, Inc., Sanofi and Teva; and received royalties from Elsevier. M.E. Wechsler reports personal fees from AstraZeneca, Boehringer Ingelheim, Equillium, Gala Therapeutics, Genentech, Genzyme, Mylan, Novartis, Pulmatrix, ResTORbio, Regeneron Pharmaceuticals, Inc., Sentien Biotechnologies and Teva; and grants and personal fees from GlaxoSmithKline and Sanofi. N. Daizadeh, U. Kapoor, R.R. Johnson, P.J. Rowe and J.A. Jacob-Nara are employees and may hold stock and/or stock options in Sanofi. B. Ortiz, A. Radwan and Y. Deniz are employees and shareholders of Regeneron Pharmaceuticals, Inc.

Figures

FIGURE 1

a) Annualised severe exacerbation rates over the treatment period and b) least squares (LS) mean change from baseline in pre-bronchodilator (pre-BD) forced expiratory volume in 1 s (FEV1) over time in patients with blood eosinophils ≥500 cells·µL−1 at baseline. c) Annualised severe exacerbation rates and d) LS mean change from baseline in pre-BD FEV1 in the overall intention-to-treat population by baseline eosinophil count. ***: p<0.001.